● Recruiting

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Condition: HER2-low Breast Cancer · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

PhasePhase 3

Planned participants566

Who can joinFemale, 18 Years to 75 Years

Healthy volunteersNo

About this study

This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Sa Xiao, PHD · 15013238943 · xiaosa@baili-pharm.com

Always discuss trial participation with your own doctor first.

Locations (2)

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University	Guangzhou, Guangdong, China	Recruiting
Hunan Cancer Hospital	Changsha, Hunan, China	Not Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06957886